Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Insight Public Affairs

We are an award winning 15-strong team of consultants able to offer extensive experience in politics, government, media and stakeholder engagement, across a breadth of policy areas including telecoms, technology, gambling, life sciences, financial services, housing, infrastructure, copyright, employment, media and advertising, food and drink, social care, retail, and education. As an independent agency we go that extra mile to deliver results-focussed communications strategies and programmes that fulfil our clients’ commercial imperatives. Working tirelessly to meet our clients’ goals, we are a team who understand client challenges, develop bespoke strategies and programmes, and meet these strategic objectives.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

- PMLiVE

Visions4Health

Visions4Health are market access experts and your gateway to local adoption at pace. Leveraging our lived experience, understanding of national and local healthcare systems, and insights generated by our stakeholder…

View Profile

Health policy and government affairs, Market access, Market research

Company Details

Insight Public Affairs
52 Grosvenor Gardens, London, SW1W 0AU, United Kingdom
+44 (0)20 7824 1865
Contact Insight Public Affairs
Website

 Latest Content from PMHub 

Infographic: Research Partnership

White Papers and Resources | May 17, 2016 | Inizio

Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.

AAD conference 2016

White Papers and Resources | May 17, 2016 | Inizio

Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients

Video: Global Biosimilars Market

White Papers and Resources | May 16, 2016 | Inizio

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Case study: Understanding Patient Willingness to Pay in Emerging Markets

White Papers and Resources | May 16, 2016 | Inizio

Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

White Papers and Resources | May 16, 2016 | Inizio

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

Lucid reach the shortlist for Communiqué 2016 in SIX categories

Press Releases | May 13, 2016 | Lucid Group Communications Limited

Lucid Group are celebrating the news that for the first time they have been shortlisted in six different categories at this year’s Communiqué awards.  The categories are:Excellence in Communications of...

The difference between market intelligence and design intelligence

White Papers and Resources | May 13, 2016 | Blue Latitude Health

Blue Latitude Health's Elisa del Galdo explains how market and customer research differ, and in which situations you would use one over the other.

Real-world engagement just got real: Leveraging consumer data and location-based signals to drive qualified reach at scale

White Papers and Resources | May 12, 2016 | Aptus Health

By Patrick Aysseh, President of Tomorrow Networks (a division of Aptus Health)

The Missing Ingredient in Online Healthcare: Trust

White Papers and Resources | May 12, 2016 | Aptus Health

By Brad Davidson, PhD, SVP Strategic Planning, Aptus Health

Lucid Co-founder and COO discusses the changing landscape of healthcare communications

Press Releases | May 12, 2016 | Lucid Group Communications Limited

In May’s issue, Jan Steele (Lucid co-founder and COO) talks to PME about the importance of demonstrating value with medical education via validated improvements in patient outcomes. Jan explains that...